ライフサイエンスコーパス: fulminant hepatitis

1 also protected mice from endotoxin shock and fulminant hepatitis.

2 sig4 in mice ameliorates MHV-3-induced viral fulminant hepatitis.

3 c HBV infection, but might prevent infantile fulminant hepatitis.

4 genotype 2a strain JFH-1 from a patient with fulminant hepatitis.

5 sion, and similar mortality from Fas-induced fulminant hepatitis.

6 BC, alcohol, primary biliary cirrhosis, and fulminant hepatitis.

7 maRII, leads to severe hemorrhage and lethal fulminant hepatitis.

8 agnosed 10 months after liver transplant for fulminant hepatitis.

9 ression in mice would reduce the severity of fulminant hepatitis.

10 HGV RNA is not causally related to non-A-E fulminant hepatitis.

11 f 14 of the 36 patients (38.8%) with non-A-E fulminant hepatitis.

12 blood product transfusion after the onset of fulminant hepatitis.

13 HCV-positive patients; no patients developed fulminant hepatitis.

14 agothrix lagotricha) that was suffering from fulminant hepatitis.

15 ase (CLD) has been associated with severe or fulminant hepatitis.

16 cessive copper accumulation in the liver and fulminant hepatitis.

17 The two prolines (P310 and P341 of Japanese fulminant hepatitis 1 [JFH-1]) contained in these motifs

18 that the H316N mutation rendered a Japanese fulminant hepatitis 1 chimeric HCV genome encoding the g

19 human hepatocytes infected with the Japanese fulminant hepatitis 1 HCV strain as well as in biopsies

20 cells, and approximately 90% in J6/Japanese fulminant hepatitis 1 HCV-infected cells without affecti

21 icon cells, approximately 70% in J6/Japanese fulminant hepatitis 1 HCV-transfected cells, and approxi

22 ent populations of immune cells and Japanese fulminant hepatitis-1 (JFH-1) HCV-infected Huh7.5 (cell

23 ted/founder virus, sucrose-purified Japanese fulminant hepatitis-1 (JFH-1), a virus encoding a lucife

24 When HCV Japanese fulminant hepatitis-1 (JFH-1)-infected hepatocytes were

25 and primary human hepatocytes with Japanese fulminant hepatitis-1 (JFH1) HCV cell culture system (HC

26 The Japanese fulminant hepatitis-1 (JFH1)-based hepatitis C virus (HC

27 th high prevalence in Japanese patients with fulminant hepatitis and chronic liver disease of unknown

28 were given LPS and D-galactosamine to induce fulminant hepatitis and MCC950 to specifically inhibit N

29 ida (intra-abdominal bleeding), Aspergillus (fulminant hepatitis), and cryptococcal (symptomatic cyto

30 2%) were admitted to hospital, two developed fulminant hepatitis, and one needed a liver transplant;

31 currence with active replication and died of fulminant hepatitis B and delta recurrence.

32 2000, 21 acute HBV infections, including 10 fulminant hepatitis B cases, were identified.

33 All patients with fulminant hepatitis B died (case-fatality rate = 47.6%).

34 ons previously described in association with fulminant hepatitis B.

35 duced the severity of acetaminophen-mediated fulminant hepatitis, but was without effect on concanava

36 Deaths from fulminant hepatitis C are rare.

37 No major liver-related complications (e.g., fulminant hepatitis, decompensated liver, and hepatocell

38 Infantile fulminant hepatitis developed in 1 of 1050 children who

39 ine hepatitis virus strain-3 (MHV-3)-induced fulminant hepatitis due to excessive macrophage-dependen

40 an HBV strain associated with an outbreak of fulminant hepatitis (FH strain).

41 Fulminant hepatitis (FH) is a disease characterized by m

42 as been proposed as the etiological agent of fulminant hepatitis (FH) or hepatitis-associated aplasti

43 tic failure caused by drugs, the etiology of fulminant hepatitis (FH) remains unknown in many patient

44 Mice treated with HDAD-Ipf1 developed fulminant hepatitis, however, because of the exocrine-di

45 the severity of peritoneal inflammation and fulminant hepatitis in mice.

46 duced lethality following endotoxin-mediated fulminant hepatitis in mice.

47 oimmune hepatitis can present as an acute or fulminant hepatitis in the absence of pre-existent fibro

48 nfected mice showed decreased mortality from fulminant hepatitis induced by administration of LPS or

49 th ISIS 22023 completely protected mice from fulminant hepatitis induced by agonistic Fas antibody, b

50 In a more fulminant hepatitis induced by injecting agonistic Fas-s

51 T cell-mediated fulminant hepatitis is a life-threatening event for whic

52 re promoter of an HBV strain associated with fulminant hepatitis leading to highly (15-fold) enhanced

53 eristic patterns of liver regeneration after fulminant hepatitis may be seen at CT and MR imaging.

54 s G virus (HGV) in patients with cryptogenic fulminant hepatitis (non-A-E FH).

55 ssential for protection against ConA-induced fulminant hepatitis since only A3R-expressing mice were

56 ore-severe acute peritoneal inflammation and fulminant hepatitis than control mice.

57 nomic replicon cells or genotype 2a Japanese fulminant hepatitis type 1 (JFH-1) virus-infected hepato

58 We show that viral production of Japanese fulminant hepatitis type 1 increases 1,000-fold when cel

59 h-titer infectious virus as well as Japanese fulminant hepatitis type 1, H77/C3, and Con1/C3.

60 Three patients with fulminant hepatitis underwent CT before orthotopic liver

61 f severe end-stage liver diseases and infant fulminant hepatitis were significantly lower in the vacc

62 romoter mutant implicated in the outbreak of fulminant hepatitis, which was caused by the neighboring